Cynata Therapeutics Limited ( (AU:CYP) ) just unveiled an update.
Cynata Therapeutics Limited announced the expiration of its 18,104,720 listed CYPOA options, which will lapse if not exercised by April 1, 2025. Each option allows the holder to purchase one ordinary share at $0.30, and the expiration could impact the company’s capital structure and investor decisions, as the current share price is below the exercise price.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company specializing in stem cell and regenerative medicine. The company focuses on developing therapies using its proprietary Cymerus™ stem cell platform technology, which utilizes induced pluripotent stem cells and mesenchymoangioblasts to produce cell therapy products at a commercial scale. Cynata’s product candidates have shown positive results in clinical trials for conditions such as steroid-resistant acute graft versus host disease and diabetic foot ulcers, with ongoing trials for other diseases.
YTD Price Performance: -27.37%
Average Trading Volume: 3,300
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $32.95M
Learn more about CYP stock on TipRanks’ Stock Analysis page.